While the exact resistance mechanism has not yet been determined, EphB4 is overexpressed in bevacizumab-resistant ovarian cancer SKOV3 xenograft and co-administration of bevacizumab with the EphB4 blocker, NVP-BHG712, results in reversal of resistance and inhibition of tumor growth[79]. This evidence concerns the gene EPHB4 and neoplasm.